GREY — Grey Matters Health Share News
0.000.00%
Last trade - 00:00- CA$3.95m
- CA$4.69m
Primary Endpoint In Phase 2 Study Of Ifenprodil For Idiopathic Pulmonary Fibrosis, Chronic Cough
Brief: Algernon Pharmaceuticals Provides Update On Its Phase 1 DMT Stroke Study
Brief: Algernon Pharmaceuticals Inc -
Brief: Algernon Pharmaceuticals Announces Completion Of Enrollment In Its Phase 2 Study Of Ifenprodil For IPF And Chronic Cough
Brief: Algernon Pharmaceuticals Files For Clinical Trial And Ethics Approval For Phase 1 DMT Human Stroke Study
Brief: Algernon Pharmaceuticals Appoints James Kinley As CFO Effective From December 1, 2021
Brief: Algernon Pharmaceuticals Establishes 6 Hours As Optimum Treatment Period For DMT In Neuron Study
Brief: Algernon Pharmaceuticals Announces Receipt Of CAD$2 Mln Cash Refund From Australian Research Program
Brief: Algernon Files Meeting Request With Mhra For Use Of Dmt In Phase 1/2A Human Stroke Study
Brief: Algernon Pharmaceuticals Inc Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
Brief: Algernon Files FDA Pre-IND Meeting Request For Lung Cancer Treatment Study
Brief: Algernon Pharmaceuticals Inc Announces The Appointment Of Dr. Mark Williams To The Board Of Directors
Brief: Algernon Announces Plans For A Phase 2 Ifenprodil Chronic Cough Study In The U.S.
Brief: Algernon Pharmaceuticals Announces Appointment Of Harry Bloomfield, Qc. As A New Board Director And Chairman
Brief: Algernon Pharmaceuticals Announces It Will Not Advance Ifenprodil Into Phase 3 Trial For Covid-19
Advisory: Alert wrongly tagged to Horizons Psychedelic Stock Index ETF withdrawn
Brief: Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 In Phase 2b/3 COVID Study
Brief: Algernon Pharmaceuticals To File End-Of-Phase 2 Meeting Request With U.S. FDA For Possible Ifenprodil Phase 3 Covid-19 Trial
Brief: Algernon Pharmaceuticals Announces Topline Data From Its Phase 2B/3 Covid-19 Trial Of Ifenprodil